Literature DB >> 27703433

Corrigendum: Discoidin Domain Receptors: Potential Actors and Targets in Cancer.

Hassan Rammal1, Charles Saby1, Kevin Magnien1, Laurence Van-Gulick1, Roselyne Garnotel1, Emilie Buache1, Hassan El Btaouri1, Pierre Jeannesson1, Hamid Morjani1.   

Abstract

[This corrects the article on p. 55 in vol. 7, PMID: 27014069.].

Entities:  

Keywords:  cancer; cell signaling; collagen; discoidin domain receptors; extracellular matrix; targeted therapy; tyrosine kinase

Year:  2016        PMID: 27703433      PMCID: PMC5043063          DOI: 10.3389/fphar.2016.00346

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


Corrigendum

Following relevant reader's comments and Editor's request, my co-authors and I would like to add some references which have been unintentionally omitted in some sections of the review. We thank the readers and the Editorial Office for pointing this out and helping us to improve the manuscript.

“Introduction section” (page 2)

After surgery, radiation therapy (RT) has long been an integral component of cancer care. It is usually employed to locally eradicate tumor cells as well as alter tumor stroma with either curative or palliative intent (Hodge et al., 2012; Kwilas et al., 2012). Therefore, current efforts have been focusing on understanding the molecular, cellular, and systemic processes driving cancer initiation, progression, heterogeneity, and metastatic spread (Ramos and Bentires-Alj, 2015; Semenova et al., 2015). As a major part of the tumor ECM, type I collagen exhibits high density and altered architecture in malignant cancer and is causally linked to tumor formation and metastasis (Ren et al., 2014). Until recently, these effects on tumor cells were exclusively attributed to integrins, a major class of receptors that mediate cell interactions with extracellular matrix components. The identification of the Discoidin Domain Receptor (DDR) family as collagen receptors represents a new paradigm in the regulation of collagen-cell interactions and regulation of tumor progression (Marquez and Olaso, 2014). DDR1 and DDR2 were initially discovered by homology cloning based on their catalytic kinase domains and were orphan receptors until 1997 when Shrivastava and co-workers and Vogel and co-workers, reported that different types of collagen are functional ligands for these receptors (Leitinger, 2014). In contrast with classical growth factor tyrosine kinase receptors such as the epithelial growth factor receptor (EGFR) and fibroblast growth factor receptor (FGFR) which display a rapid and transient activation, DDR1 and DDR2 are unique in that they exhibit remarkably delayed and sustained receptor phosphorylation upon binding to collagen (Iwai et al., 2013). Furthermore, many classical tyrosine kinase receptors (RTKs) undergo negative regulation such as receptor/ligand internalization and subsequent degradation or dephosphorylation by phosphatases (Fu et al., 2013). In addition, they are uniquely positioned to function as sensors for ECM and to regulate a wide range of cell functions such as migration, cell proliferation, cytokine secretion, and ECM homeostasis/remodeling (Borza and Pozzi, 2014).

“Structure, function and regulation of DDRs” section (page 3)

DDRs control important aspects of cell behavior including proliferation, migration, adhesion, and ECM remodeling but are dysregulated in various human diseases. They are both activated by several types of collagen. However, this activation strictly requires collagen to be in its native and triple-helical conformation. Heat-denatured collagen is not recognized by DDRs (Valiathan et al., 2012; Carafoli and Hohenester, 2013). Surprisingly, the substitution of five peripheral amino acids in DDR2 with their DDR1 counterparts converts DDR2 into a receptor of type IV collagen (Carafoli and Hohenester, 2013).

Author contributions

All authors contributed to the designing, writing and the validation of the last version of the manuscript.

Funding

This work was supported by grants from Ligue Contre le Cancer 2015 (CCIR Grand-Est). CS is recipient of PhD fellowships from the French Ministry of Higher Education and Research.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  12 in total

Review 1.  Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.

Authors:  P Ramos; M Bentires-Alj
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 2.  Discoidin domain receptor tyrosine kinases: new players in cancer progression.

Authors:  Rajeshwari R Valiathan; Marta Marco; Birgit Leitinger; Celina G Kleer; Rafael Fridman
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

Review 3.  Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling.

Authors:  Hsueh-Liang Fu; Rajeshwari R Valiathan; Richard Arkwright; Anjum Sohail; Cosmin Mihai; Malika Kumarasiri; Kiran V Mahasenan; Shahriar Mobashery; Paul Huang; Gunjan Agarwal; Rafael Fridman
Journal:  J Biol Chem       Date:  2013-01-18       Impact factor: 5.157

Review 4.  Role of discoidin domain receptor 2 in wound healing.

Authors:  Joana Márquez; Elvira Olaso
Journal:  Histol Histopathol       Date:  2014-04-29       Impact factor: 2.303

5.  Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial-mesenchymal transition programme under hypoxia.

Authors:  Tingting Ren; Wei Zhang; Xinping Liu; Hu Zhao; Jian Zhang; Jing Zhang; Xia Li; Yan Zhang; Xin Bu; Man Shi; Libo Yao; Jin Su
Journal:  J Pathol       Date:  2014-09-15       Impact factor: 7.996

Review 6.  Discoidin domain receptors in disease.

Authors:  Corina M Borza; Ambra Pozzi
Journal:  Matrix Biol       Date:  2013-12-19       Impact factor: 11.583

7.  In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.

Authors:  Anna R Kwilas; Renee N Donahue; Michael B Bernstein; James W Hodge
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

Review 8.  Origins, genetic landscape, and emerging therapies of small cell lung cancer.

Authors:  Ekaterina A Semenova; Remco Nagel; Anton Berns
Journal:  Genes Dev       Date:  2015-07-15       Impact factor: 11.361

9.  Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.

Authors:  Leo K Iwai; Leo S Payne; Maciej T Luczynski; Francis Chang; Huifang Xu; Ryan W Clinton; Angela Paul; Edward A Esposito; Scott Gridley; Birgit Leitinger; Kristen M Naegle; Paul H Huang
Journal:  Biochem J       Date:  2013-09-15       Impact factor: 3.857

Review 10.  Discoidin domain receptor functions in physiological and pathological conditions.

Authors:  Birgit Leitinger
Journal:  Int Rev Cell Mol Biol       Date:  2014       Impact factor: 6.813

View more
  5 in total

1.  DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study.

Authors:  Meng-Chen Tsai; Wei-Ming Li; Chun-Nung Huang; Hung-Lung Ke; Ching-Chia Li; Hsin-Chih Yeh; Ti-Chun Chan; Peir-In Liang; Bi-Wen Yeh; Wen-Jeng Wu; Sher-Wei Lim; Chien-Feng Li
Journal:  Oncotarget       Date:  2016-11-29

2.  Discoidin Domain Receptor 1 Expression in Colon Cancer: Roles and Prognosis Impact.

Authors:  Kaouther Ben Arfi; Christophe Schneider; Amar Bennasroune; Nicole Bouland; Aurore Wolak-Thierry; Guillaume Collin; Cuong Cao Le; Kevin Toussaint; Cathy Hachet; Véronique Lehrter; Stéphane Dedieu; Olivier Bouché; Hamid Morjani; Camille Boulagnon-Rombi; Aline Appert-Collin
Journal:  Cancers (Basel)       Date:  2022-02-13       Impact factor: 6.639

3.  Matrix stiffness exacerbates the proinflammatory responses of vascular smooth muscle cell through the DDR1-DNMT1 mechanotransduction axis.

Authors:  Jin Wang; Si-An Xie; Ning Li; Tao Zhang; Weijuan Yao; Hucheng Zhao; Wei Pang; Lili Han; Jiayu Liu; Jing Zhou
Journal:  Bioact Mater       Date:  2022-01-14

4.  Integrated Workflow for the Label-Free Isolation and Genomic Analysis of Single Circulating Tumor Cells in Pancreatic Cancer.

Authors:  Brittany Rupp; Sarah Owen; Harrison Ball; Kaylee Judith Smith; Valerie Gunchick; Evan T Keller; Vaibhav Sahai; Sunitha Nagrath
Journal:  Int J Mol Sci       Date:  2022-07-16       Impact factor: 6.208

5.  Inhibition of discoidin domain receptors by imatinib prevented pancreatic fibrosis demonstrated in experimental chronic pancreatitis model.

Authors:  Sapana Bansod; Mohd Aslam Saifi; Chandraiah Godugu
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.